Trials / Completed
CompletedNCT04198415
A Study of the Safety and Efficacy of Venetoclax in Japanese Participants With Relapsed and Refractory Chronic Lymphocytic Leukemia (Including Small Lymphocytic Leukemia)
Post-Marketing All-Patient Drug Use Results Study for Venetoclax in Japanese Patients With Relapsed and Refractory Chronic Lymphocytic Leukemia (Including Small Lymphocytic Leukemia)
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 4 (actual)
- Sponsor
- AbbVie · Industry
- Sex
- All
- Age
- —
- Healthy volunteers
- Not accepted
Summary
This study will collect real-world safety and efficacy data from Japanese relapse/refractory chronic lymphocytic leukemia (CLL) and small lymphocytic leukemia (SLL) participants treated with venetoclax.
Conditions
Timeline
- Start date
- 2020-02-03
- Primary completion
- 2022-10-21
- Completion
- 2022-10-21
- First posted
- 2019-12-13
- Last updated
- 2023-10-19
Locations
102 sites across 1 country: Japan
Source: ClinicalTrials.gov record NCT04198415. Inclusion in this directory is not an endorsement.